ABPI new Phase I guidelines expected

19 March 2007

A year after the disastrous TGN1412 Phase I clinical trial at Northwick Park, UK, which caused severe adverse reactions in six people (Marketletters passim), a spokesman for the Association of the British Pharmaceutical Industry has confirmed that the trade association is currently revising its guidelines for members carrying out such trials.

Richard Tiner, the ABPI's medical director, told the Financial Times that the insurance level of L2.0 million ($3.9 million) by the German drugmaker TeGenero was lower than the level recommended by the trade body. An insurance level of about L5.0 million would have been more appropriate, an ABPI representative told the Marketletter.

Despite having published proposals for new guidelines last year, these have not yet been ratified by the ABPI. Richard Ley, a spokesman for the ABPI told the Marketletter that the internal guidelines had been in the process of being revised at the time of the TGN1412 incident. This review was suspended, in order that any lessons could be taken into account from the UK government-commissioned report by Gordon Duff into the trial's failure. The ABPI and the BioIndustry Association produced a set of proposals for improving clinical trial procedures and submitted them for consideration by Prof Duff's inquiry (Marketletter July 31, 2006), which were broadly adopted. Mr Ley added that the revised guidelines should be in place "within weeks rather than months."

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight